GT Biopharma Uses AI to Fast-Track Pre-IND Tumor-Targeting Drugs
XNCR•GT Biopharma has deployed AI-guided sequence and structural analysis across discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, aiming to advance multiple new candidates into pre-IND development by 2027. These efficiency gains coincide with its TriKE platform’s Phase 1 trials, pressuring Xencor’s antibody-engineering pipeline competitiveness.
1. AI Integration in Drug Discovery
GT Biopharma has embedded AI-based tools into its discovery and protein-engineering workflow, applying sequence and structural analyses to identify tumor-targeting NK cell engagers and multi-domain proteins with optimal binding, stability and developability profiles.
2. Efficiency Gains and Pre-IND Candidates
The company forecasts that AI-driven prioritization will push multiple new development candidates into pre-IND studies by 2027, aiming to reduce discovery timelines and lower costs associated with late-stage failures.
3. Ongoing Clinical Programs
Its TriKE platform supports two Phase 1 trials: GTB-3650 for CD33-expressing blood cancers and GTB-5550 for B7-H3 solid tumors, with the first GTB-5550 patient dosed in May 2026, underscoring near-term pipeline validation.
4. Implications for Competitors
Accelerated candidate generation and reduced development costs may intensify competition for antibody-engineering specialists like Xencor, as GT Biopharma seeks to expand its pipeline beyond oncology and secure earlier entry into IND-enabling studies.
